These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 25511188)
21. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862 [TBL] [Abstract][Full Text] [Related]
22. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412 [TBL] [Abstract][Full Text] [Related]
23. Case of hypophysitis caused by nivolumab. Ishikawa M; Oashi K J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147 [No Abstract] [Full Text] [Related]
24. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333 [TBL] [Abstract][Full Text] [Related]
25. Nivolumab: A Review in Advanced Melanoma. Scott LJ Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912 [TBL] [Abstract][Full Text] [Related]
31. Upcoming strategies for the treatment of metastatic melanoma. Spagnolo F; Queirolo P Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184 [TBL] [Abstract][Full Text] [Related]
32. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Michielin O; Hoeller C Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079 [TBL] [Abstract][Full Text] [Related]
33. Therapy of metastatic malignant melanoma: on the way to individualized disease control. Vogt T Adv Exp Med Biol; 2014; 810():272-81. PubMed ID: 25207371 [TBL] [Abstract][Full Text] [Related]
34. The brothers RAF. Kwong LN; Chin L Cell; 2010 Jan; 140(2):180-2. PubMed ID: 20141832 [TBL] [Abstract][Full Text] [Related]
35. Metastatic melanoma treatment: Combining old and new therapies. Davey RJ; van der Westhuizen A; Bowden NA Crit Rev Oncol Hematol; 2016 Feb; 98():242-53. PubMed ID: 26616525 [TBL] [Abstract][Full Text] [Related]
36. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390 [TBL] [Abstract][Full Text] [Related]
37. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. Long G Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501 [No Abstract] [Full Text] [Related]
39. Combination Therapies for Melanoma: A New Standard of Care? Smalley KS; Eroglu Z; Sondak VK Am J Clin Dermatol; 2016 Apr; 17(2):99-105. PubMed ID: 26860106 [TBL] [Abstract][Full Text] [Related]